Gilead Sciences Ireland UC filed an opposition to prevent Vertex Pharmaceuticals Incorporated from registering the trademark VOCEMIVY with the USPTO. The opposition was filed on April 3, 2026 (TTAB docket TTAB91306359). The basis for opposition is not specified in this notice, but typical grounds include likelihood of confusion with existing marks, descriptiveness, or genericness.

Vertex Pharmaceuticals must respond to the opposition by filing an answer within 40 days of service of the Notice of Opposition, per TTAB rules. The parties may engage in discovery followed by a trial period. Gilead may seek to amend its pleaded marks or assert additional claims as the proceeding advances. Settlement negotiations are common in TTAB proceedings.